

TK1 together with PSA can predict more than 10 years differences in survival in men with prostate cancer.

In a study carried out by a research group at Karolinska Hospital and Karolinska Institute, it appears that the combination of TK1 and PSA provides a new biomarker that can early indicate survival in prostate cancer patients.

A peer-reviewed article on Thymidine kinase 1 (TK1) has been published in the International Journal of Molecular Science. The study, entitled: *Prediction of overall survival by thymidine kinase 1 combined with prostate specific antigen in men with prostate cancer*, was done by a research group at Karolinska Institute and Karolinska Hospital.

TK1 was analyzed with AroCells TK210 ELISA in 30-year-old blood samples from a prostate cancer screening executed at Södersjukhuset in 1988-89. TK1 was combined with PSA into one biomarker. Though PSA is the most used blood marker for diagnosis and follow-up of prostate cancer, it is limited by the fact that there are many non-cancer-related reasons for increased PSA values, such as age. TK1, on the other hand, is found to be independent of age and other prostate-related characteristics. The combination of TK1 and PSA identified subgroups of men with more than 10 years difference in survival time. This enables individual treatment of high-risk patients.

The main author, Bernhard Tribukait explains: *"Prostate cancer is usually slow-growing and does not always cause symptoms or problems for the patient. Many treatments have side effects that can have a major impact on the patient's quality of life. Therefore, it is important to be able to distinguish the aggressiveness of the tumor at an early stage. A combination of blood-based biomarkers at low cost can be very valuable, for example, in the choice between active surveillance and radical surgery. In many cases, it can reduce suffering for patients and costs for healthcare."*

Contacts

Anders Hultman, CEO
Phone: +46 (0) 8 799 67 50
E-mail: anders.hultman@arocell.com

About TK 210 ELISA

AroCell TK 210 ELISA is a quantitative immunoassay kit for the determination of Thymidine Kinase 1 (TK1) in human blood. The ELISA format is simple and robust, requires no special instrumentation to perform and can easily be incorporated into standard laboratory processes. By utilizing monoclonal antibodies specific for the TK1 epitope TK 210, AroCell TK 210 ELISA brings improved sensitivity and specificity to the assay of this key biomarker. AroCell TK 210 ELISA provides new opportunities for studying cellular proliferation, disruption, and monitoring of therapy response and relapse in subjects with haematological and solid tumours.

About AroCell

AroCell AB (publ) is a Swedish company that develops and markets blood and urine sample tests. The corporation specializes in oncology and bacteriology. The company has a broad product portfolio, used in healthcare, and established in various markets. In oncology, AroCell uses various biomarkers, TK1, and cytokeratins, to support the treatment of various cancers such as breast, prostate, and bladder cancers. AroCell's product portfolio also includes a rapid bacteriological test for a simple and safe diagnosis of typhoid fever. AroCell (AROC) is listed on Nasdaq First North Growth Market with Redeye AB as company's Certified Adviser. For more information; www.arocell.com

Attachments

[TK1 together with PSA can predict more than 10 years differences in survival in men with prostate cancer.](#)